Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000 biotechnology companies, academic institutions, and research centers across the United States.I am John Crowley, President and CEO of BIO. For me, the future of biotech and delivering lifesaving cures to patients isn’t just professional — it’s deeply personal.Twenty-five years ago, my two youngest children, Megan and Patrick, were diagnosed with Pompe disease, a rare and fatal neuromuscular disorder. At the time, there was no treatment — no hope beyond comfort care. I left my job, went back to graduate school, and eventually helped start a small biotech company dedicated to developing an enzyme replacement therapy.That therapy — born from the ingenuity and perseverance of American scientists, and approved by the FDA — gave my children a chance at life. Today, Megan and Patrick are living full, meaningful lives.That experience taught me two things I will never forget: first, that science can save lives, and second, the biotech ecosystem is complex, interdependent, and each piece is critical for success.So when I speak today about America’s biotechnology ecosystem and our global competitiveness, I speak not only as a CEO, but as a father who owes everything to innovation and the people who make it possible.BIO’s members are developing new medicines, vaccines and technologies that improve and save American lives. Biotechnology not only strengthens our nation’s health, and is a key driver for the U.S. economy, but is also critical for our national security. We are deeply committed to ensuring that the Food and Drug Administration (FDA) remains the global gold standard for medical product regulation — protecting public health while ensuring that patients have timely access to safe and effective treatments, but also that the United States…